A comprehensive pathophysiology diagram illustrating the human coagulation cascade and the specific pharmacodynamic sites of action for various anticoagulants. The diagram is divided into three functional zones: the Intrinsic Pathway (blue), starting with Factor XII; the Extrinsic Pathway (red), initiated by Tissue Factor (TF) and Factor VII; and the Common Pathway (purple), where the pathways converge at Factor X. The cascade terminates in the conversion of Fibrinogen (I) to Fibrin (Ia), forming a fibrin clot. A secondary visual element depicts a platelet clot associated with the extrinsic pathway. Key clinical pharmacotherapeutic targets are marked with color-coded symbols: Warfarin inhibits Factors IX, VII, X, and II; Unfractionated Heparin (UHEP) + Antithrombin III (ATIII) inactivates Factors XIIa, XIa, IXa, Xa, and IIa; Low-Molecular-Weight Heparin (LMWHEP) and Fondaparinux target Factor Xa; Direct Factor Xa inhibitors act on Factor Xa; and Dabigatran acts as a direct thrombin inhibitor (Factor IIa). This schematic is designed for medical education regarding hemostasis and thromboprophylaxis.

This pathophysiology diagram illustrates the dual activation of the coagulation cascade in patients undergoing Extracorporeal Membrane Oxygenation (ECMO). The diagram identifies two primary initiation mechanisms: contact with the artificial surface of the ECMO system and interactions with the vascular endothelium. The intrinsic pathway is triggered by the artificial surface, involving the contact system where Factor XII is activated to XIIa. This initiates a cascade (XIIa to XIa, XIa to IXa, and IXa to Xa) and a self-amplification loop involving Prekallikrein to Kallikrein and HMWK to Bradykinin. Concurrently, the extrinsic pathway is activated by soluble Tissue Factor (TF) released from the vascular endothelium and TF expressed on monocytes, leading to Factor VIIa activating Factor X to Xa. Both pathways converge at the common pathway, where Factor Xa converts Prothrombin to Thrombin. Thrombin subsequently leads to platelet activation (PLT), thrombus formation, and the release of proinflammatory cytokines, specifically IL-6 and TNF-α. The graphic serves as a clinical education tool for understanding the thrombotic and inflammatory risks associated with extracorporeal life support.

Summary : This diagram illustrates the traditional coagulation cascade, detailing the sequence of events and factors involved in blood clotting via the intrinsic, extrinsic, and common pathways. flowchart: # Pathways : • Intrinsic pathway (green box): Initiated by factor XII, proceeds through XI, IX, and VIII, with activation steps indicated by "a" (e.g., XIIa, XIa, IXa). • Extrinsic pathway (red box): Initiated by tissue damage, which activates tissue factor (TF) and factor VIIa. • Common pathway (blue box): Both intrinsic and extrinsic pathways converge at factor X, leading to the activation of prothrombin to thrombin, which then converts fibrinogen to fibrin, forming a fibrin clot. # Nodes : • XII → XIIa (Intrinsic) • XI → XIa (Intrinsic) • IX → IXa (Intrinsic) • Ca²⁺, PT, V (Intrinsic, Common) • TF/VIIa (Extrinsic) • Tissue damage (Extrinsic) • X → Xa (Common) • Prothrombin → Thrombin (Common) • Fibrinogen → Fibrin (Common) • XIII (Common) • Fibrin clot (Common) # Connectors : • Arrows indicate the direction of activation or conversion between factors. • Intrinsic and extrinsic pathways both feed into the activation of factor X in the common pathway. • Ca²⁺ and PT, V are required cofactors at specific steps. # Layout : • Three main colored sections: green (intrinsic, top left), red (extrinsic, top right), blue (common, bottom). • Flow proceeds from top (initiation) to bottom (clot formation). • Arrows show sequential activation and convergence of pathways. # Analysis : • The diagram clearly separates the intrinsic and extrinsic initiation mechanisms, both converging on the common pathway at factor X. • The cascade is highly sequential, with each activated factor catalyzing the next step. • Calcium ions (Ca²⁺) and phospholipids (PT) are essential cofactors at multiple steps. • The final outcome is the formation of a stable fibrin clot, highlighting the coordinated nature of the coagulation process.

<table> <tr> <th></th> <th>2010 Prior Guideline Recommendation</th> <th>2023 Update Guideline Recommendation</th> </tr> <tr> <td>Thromboelastography may be useful during the HT surgery to further elucidate the status of the patient’s hemostasis.<br>Class IIa, Level of Evidence C</td> <td>Perioperative viscoelastic tests, thromboelastography (TEG) and rotational thromboelastometry (ROTEM), may be useful in HT surgery to analyze full clot formation profiles, including platelet function, in further elucidating the recipient’s anticoagulation status.<br><b>Class IIa, Level of Evidence C</b></td> </tr> <tr> <td>Fibrinogen levels and D-Dimer values should be measured postoperatively because these are tests of fibrinolysis and correlate with the risk of bleeding after HT surgery.<br>Class IIa, Level of Evidence C</td> <td>Postoperative measurements of fibrinogen and D-dimer values, which correlate with increased risk of bleeding after HT may be measured in recipients identified as having specific increased risks for vascular thrombosis.<br><b>Class IIb, Level of Evidence C</b></td> </tr> <tr> <td>Platelet function can be measured either by platelet aggregometry or by a point of care assay such as the platelet function assay 100 (PFA-100) during the HT surgery.<br>Class IIa, Level of Evidence C</td> <td>Continuing approval without change</td> </tr> <tr> <td>Thromboelastography may be repeated after HT surgery to monitor patients’ hemostasis.<br>Class IIa, Level of Evidence C</td> <td><b>Recommendation removed</b></td> </tr> </table>

Educational panel consisting of a surgical diagram, a longitudinal line graph, and diagnostic tracing images related to a pediatric neurosurgical case. Panel A: An anatomical diagram illustrating a left frontotemporal craniotomy on an infant. The illustration shows a reflected scalp flap held by retractors, exposing an abnormal skull surface characterized by thinning and distinctive dark-red, worm-like vascular changes and blood seeping, indicative of tumor invasion. Panel B: A line graph tracking coagulative indicators from pre-operative status through 360 days post-operative. Platelet count (plt, x10^9/L) is shown in red, and fibrinogen (fib, g/L) in blue. The graph demonstrates a sharp perioperative decline in both markers followed by a recovery phase peaking around day 10–20. Panel C: Pre-operative and post-operative Thromboelastography (TEG) tracings showing normal clot formation kinetics, including R-time, K-time, alpha angle, and Maximum Amplitude (MA). The tracings represent a stable coagulation profile despite the significant surgical intervention for a suspected intracranial Kaposiform Hemangioendothelioma (KHE).

This medical infographic presents three clinical algorithms (A, B, and C) for managing massive bleeding in acute settings. Algorithm A details a ROTEM-guided approach for uncoagulated patients, using viscoelastic parameters (EXTEM, FIBTEM, APTEM) to differentiate and treat hyperfibrinolysis (tranexamic acid), hypofibrinogenemia (fibrinogen concentrate), thrombin deficiency (prothrombin complex), and thrombocytopenia. Algorithm B outlines management for uncoagulated patients when ROTEM is unavailable, focusing on monitoring for the 'lethal triad' (acidosis, hypothermia, coagulopathy), lab values like hemoglobin and base excess, and the administration of blood products or PCC. Algorithm C addresses oral anticoagulant overdose, branching by agent type: Vitamin K Antagonists (VKA) or Direct Oral Anticoagulants (DOACs). It provides decision nodes based on INR levels and hemorrhage severity, recommending reversal agents such as Vitamin K, prothrombin complex (PCC), or Idarucizumab for dabigatran. The diagrams use standardized medical terminology and dosage guidelines suitable for emergency medicine, hematology, and trauma surgery education.